CGT is rapidly transforming oncology and rare disease research, with patient-derived models, advanced imaging, CRISPR/Cas9, and 3D organoids driving innovation while solid tumor modeling remains a critical frontier.
Benjamin Wilkin
Advertisement
Benjamin Wilkin is product marketing manager at Crown Bioscience.
Articles by Benjamin Wilkin
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
3
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
4
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
5